266 related articles for article (PubMed ID: 6610851)
21. [EEG-slowing after high-dose Methotrexate with citrovorumfactor-rescue. A spectralanalytic study (author's transl)].
Korinthenberg R; Lütkenhöner B; Palm D; Ritter J
EEG EMG Z Elektroenzephalogr Elektromyogr Verwandte Geb; 1982 Mar; 13(1):22-7. PubMed ID: 6806066
[TBL] [Abstract][Full Text] [Related]
22. [Toxicosis of high-dose methotrexate (HD-MTX) for osteosarcoma, cured with treatment by leucovorin (LV) rescue and hemoperfusion--a case report].
Kobayashi H; Morita T; Hirata Y; Kato T; Okada Y; Sato T
Gan To Kagaku Ryoho; 2000 Mar; 27(3):475-8. PubMed ID: 10740644
[TBL] [Abstract][Full Text] [Related]
23. [Results and pharmacokinetic aspects of methotrexate therapy in high doses].
Lenzhofer R; Jaschek I; Breyer S; Graninger W; Moser K
Acta Med Austriaca Suppl; 1979; 6():331-3. PubMed ID: 318045
[TBL] [Abstract][Full Text] [Related]
24. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
[TBL] [Abstract][Full Text] [Related]
25. Significance of the 48-hour plasma level in high-dose methotrexate regimens.
Perez C; Wang YM; Sutow WW; Herson J
Cancer Clin Trials; 1978; 1(2):107-11. PubMed ID: 316368
[TBL] [Abstract][Full Text] [Related]
26. Use of plasma exchange in methotrexate removal in a patient with osteosarcoma and acute renal insufficiency.
Cecyn KZ; Lee J; Oguro T; Petrilli AS; Bordin JO
Am J Hematol; 2003 Mar; 72(3):209-11. PubMed ID: 12605394
[TBL] [Abstract][Full Text] [Related]
27. [High-dose methotrexate with citrovorum factor rescue (HD-MTX-CFR) in the treatment of malignant solid tumors--clinical analysis of 62 patients].
Wang QL; Sun Y; Zhou JC; Song SZ; Feng FY; Lu L; Yie ZS
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):152-4. PubMed ID: 3264785
[TBL] [Abstract][Full Text] [Related]
28. Improved therapeutic index with high-dose methotrexate: comparison of thymidine-purine rescue with citrovorum factor rescue in mice.
Samuels LL; Straw JA
Cancer Res; 1984 Jun; 44(6):2278-84. PubMed ID: 6609764
[TBL] [Abstract][Full Text] [Related]
29. [Preliminary evaluation of individualized use of large doses of methotrexate for treatment of osteosarcoma in children and adolescents].
Perek D; Jurczyk-Procyk S; Prokopczyk J; Piekarczyk A; Zelazowski J; Dembowska-Bagińska B; Wieckowska J; Witkowska-Ozogowska J; Kozera M
Pediatr Pol; 1995 Nov; 70(11):929-37. PubMed ID: 8677159
[TBL] [Abstract][Full Text] [Related]
30. Early recognition of renal toxicity of high-dose methotrexate therapy: a case report.
Nowicki TS; Bjornard K; Kudlowitz D; Sandoval C; Jayabose S
J Pediatr Hematol Oncol; 2008 Dec; 30(12):950-2. PubMed ID: 19131789
[TBL] [Abstract][Full Text] [Related]
31. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
[TBL] [Abstract][Full Text] [Related]
32. Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors.
Pratt CB; Roberts D; Shanks EC; Warmath EL
Cancer Res; 1974 Dec; 34(12):3326-31. PubMed ID: 4547680
[No Abstract] [Full Text] [Related]
33. [l-folinic acid versus racemic folinic acid in the treatment of leukemia in children with high dose of methotrexate].
Etienne MC; Thyss A; Bertrand Y; Rubie H; Milano G
Bull Cancer; 1993 Apr; 80(4):357-63. PubMed ID: 8173189
[TBL] [Abstract][Full Text] [Related]
34. [Management of the administration of leucovorin calcium in high-dose methotrexate therapy].
Kickinger W; Ritschl P; Kotz R
Arzneimittelforschung; 1989 Jun; 39(6):728-31. PubMed ID: 2789050
[TBL] [Abstract][Full Text] [Related]
35. Calculated versus measured creatinine clearance for dosing methotrexate in the treatment of primary central nervous system lymphoma.
Gerber DE; Grossman SA; Batchelor T; Ye X
Cancer Chemother Pharmacol; 2007 May; 59(6):817-23. PubMed ID: 16972068
[TBL] [Abstract][Full Text] [Related]
36. High-dose methotrexate: pharmacokinetics in children and young adults.
Raude E; Oellerich M; Weinel P; Freund M; Schrappe M; Riehm H; Poliwoda H
Int J Clin Pharmacol Ther Toxicol; 1988 Jul; 26(7):364-70. PubMed ID: 3209285
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society.
Hartung G; Stehle G; Sinn H; Wunder A; Schrenk HH; Heeger S; Kränzle M; Edler L; Frei E; Fiebig HH; Heene DL; Maier-Borst W; Queisser W
Clin Cancer Res; 1999 Apr; 5(4):753-9. PubMed ID: 10213209
[TBL] [Abstract][Full Text] [Related]
38. High dose methotrexate in adult patients with osteosarcoma: clinical and pharmacokinetic results.
Comandone A; Passera R; Boglione A; Tagini V; Ferrari S; Cattel L
Acta Oncol; 2005; 44(4):406-11. PubMed ID: 16120550
[TBL] [Abstract][Full Text] [Related]
39. [Studies on the effect of high-dose methotrexate-citrovorum factor treatment for 89Sr induced osteosarcoma in mice (author's transl)].
Nakamura T
Nihon Seikeigeka Gakkai Zasshi; 1982 Feb; 56(2):149-61. PubMed ID: 6978919
[TBL] [Abstract][Full Text] [Related]
40. Methotrexate megadosage followed by folate rescue. I. A study in clearance patterns.
Salasoo S; Irving MG; Lam-Po0Tang R; O'Gorman-Hughes D; Freedman A
Med J Aust; 1976 May; 1(21):777-9. PubMed ID: 1085404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
